UNSPSC 51373431: Codeine/guaifenesin/phenylephrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373431 Codeine/guaifenesin/phenylephrine is a Commodity code that in recent state and local solicitations covers the procurement of generic multi-source pharmaceuticals and over-the-counter products distributed through authorized wholesalers to government health and social-service facilities. State and local buyers under this code include county health departments, state pharmaceutical cooperatives, and networked health systems across multiple jurisdictions. The scope encompasses manufacturers supplying pharmaceuticals with specified National Drug Codes, dosage forms, packaging configurations, and pricing structures (flat price, net price formats, or WAC-minus pricing) to authorized drug wholesalers for distribution to participating agencies. Vendors must certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, maintain contractual relationships with multiple authorized wholesalers, and carry comprehensive insurance including commercial general liability of $5,000,000 per occurrence and professional liability of $2,000,000. Products must meet FDA requirements and carry expiration dates of at least one year from manufacture with a minimum six-month shelf life.

Recent activity spans Minnesota and Florida, with the largest opportunity being the Minnesota Multistate Cooperative Purchasing Alliance's RFP (S1070000015802) for generic multi-source pharmaceuticals and OTC products issued January 20, 2026, with proposals due March 26, 2026, and anticipated award July 1, 2026. This cooperative procurement serves participating state and local government facilities across Minnesota and Oregon. Seminole County, Florida issued an IFB (IFB60459723LAS) posted June 30, 2026 for naloxone and drug deactivation systems with quarterly deliveries to the county community health building and a response deadline of July 26, 2023. The MMCAP RFP weights evaluation 75 percent on price competitiveness, 10 percent on fixed pricing for the contract term, and 10 percent combined on administrative compliance, EDI capability, and administrative-fee acceptance. Neither solicitation names explicit set-aside designations for disadvantaged enterprises.